Kidney Transplant Infection Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Kidney Transplant Infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

Kidney Transplant Failure and RejectionBK ViremiaKidney Transplant Infection
The University of Queensland280 enrolled12 locationsNCT05325008
Recruiting
Phase 3

Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients

Kidney Transplant Infection
University Hospital, Rouen144 enrolled1 locationNCT05708508
Recruiting
Not Applicable

The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient

BK Virus InfectionKidney Transplant Infection
King Chulalongkorn Memorial Hospital50 enrolled1 locationNCT04542733
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

Kidney Transplant Infection
University Hospital, Rouen28 enrolled1 locationNCT05708534
Recruiting
Phase 3

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

Kidney Transplant InfectionPyelonephritis Acute
Assistance Publique - Hôpitaux de Paris470 enrolled9 locationsNCT05597540